Acumen Pharmaceuticals (ABOS) Liabilities and Shareholders Equity (2020 - 2026)

Acumen Pharmaceuticals has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $133.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 34.65% year-over-year to $133.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $570.6 million (down 42.91% YoY) and the FY2025 annual result came in at $122.8 million, down 48.6% from the prior year.
• Liabilities and Shareholders Equity improved to $133.6 million in Q1 2026 per ABOS's latest filing, from $122.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $310.1 million in Q4 2023 and troughed at $122.8 million in Q4 2025.
• A 5-year average of $215.5 million and a median of $204.5 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 190.2% in 2022, then sank 48.6% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $196.6 million in 2022, then surged by 57.75% to $310.1 million in 2023, then retreated by 22.94% to $239.0 million in 2024, then slumped by 48.6% to $122.8 million in 2025, then advanced by 8.79% to $133.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $133.6 million, $122.8 million, and $142.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.